Let’s Keep the Door to Biotechnological Eugenics Closed
By Enola Aird,
MomsRising
| 02. 10. 2014
Remember the
three-parent babies I told you about in December? The ones made with genetic material from two different women? Well, the United States might be moving a step closer to their creation.
A Food and Drug Administration (FDA) Advisory Committee will hold a
public meeting on February 25 and 26 regarding clinical trials of mitochondrial transfer procedures (MT). I’ve submitted a written
statement and received FDA permission to present my arguments at the meeting. I’ll be there to oppose the use of such procedures because they would permanently change the genes passed down to future generations.
A quick reminder of what’s at stake. The Advisory Committee will consider whether to allow human clinical trials of “oocyte modification in assisted reproduction for the prevention of the transmission of mitochondrial disease or treatment of infertility.” That’s a long way of referring to a form of genetic modification that would alter an embryo’s genetic structure in such a way that the changes would be passed down to all future generations of the same line.
To accomplish this sci-fi sounding task, scientists would...
Related Articles
By Grace Won, KQED [with CGS' Katie Hasson] | 12.02.2025
In the U.S., it’s illegal to edit genes in human embryos with the intention of creating a genetically engineered baby. But according to the Wall Street Journal, Bay Area startups are focused on just that. It wouldn’t be the first...
By Emma Cieslik, Ms. Magazine | 11.20.2025
Several recent Biopolitical Times posts (1, 2, 3, 4) have called attention to the alarmingly rapid commercialization of “designer baby” technologies: polygenic embryo screening (especially its use to purportedly screen for traits like intelligence), in vitro gametogenesis (lab-made eggs and sperm), and heritable genome editing (also termed embryo editing or reproductive gene editing). Those three, together with artificial wombs, have been dubbed the “Gattaca stack” by Brian Armstrong, CEO of the cryptocurrency company...
By Adam Feuerstein, Stat | 11.20.2025
The Food and Drug Administration was more than likely correct to reject Biohaven Pharmaceuticals’ treatment for spinocerebellar ataxia, a rare and debilitating neurodegenerative disease. At the very least, the decision announced Tuesday night was not a surprise to anyone paying attention. Approval...